Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $113.99 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock's 50 day simple moving average is $100.99 and its two-hundred day simple moving average is $92.33. The company has a market cap of $141.96 billion, a price-to-earnings ratio of 308.08, a PEG ratio of 0.71 and a beta of 0.21.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.77%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.
Analysts Set New Price Targets
GILD has been the subject of a number of analyst reports. UBS Group increased their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Wolfe Research began coverage on Gilead Sciences in a research note on Friday, November 15th. They issued an "outperform" rating and a $110.00 price target for the company. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $104.52.
Read Our Latest Analysis on Gilead Sciences
Institutional Trading of Gilead Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp increased its stake in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the period. FMR LLC increased its stake in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. Wellington Management Group LLP increased its stake in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the period. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after purchasing an additional 749,047 shares during the period. Finally, Norges Bank purchased a new stake in Gilead Sciences in the fourth quarter worth $1,789,254,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
